CN105473153A - 包含具有减小的免疫原性的经修饰的噬菌体g3p氨基酸序列的多肽 - Google Patents

包含具有减小的免疫原性的经修饰的噬菌体g3p氨基酸序列的多肽 Download PDF

Info

Publication number
CN105473153A
CN105473153A CN201480030678.2A CN201480030678A CN105473153A CN 105473153 A CN105473153 A CN 105473153A CN 201480030678 A CN201480030678 A CN 201480030678A CN 105473153 A CN105473153 A CN 105473153A
Authority
CN
China
Prior art keywords
seq
amino acid
nothing
polypeptide
seqidno
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480030678.2A
Other languages
English (en)
Chinese (zh)
Inventor
F.J.卡尔
T.D.琼斯
R.A.费希尔
R.G.E.霍尔盖特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Proclara Biosciences Inc
Original Assignee
NeuroPhage Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NeuroPhage Pharmaceuticals Inc filed Critical NeuroPhage Pharmaceuticals Inc
Publication of CN105473153A publication Critical patent/CN105473153A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14111—Inoviridae
    • C12N2795/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14111—Inoviridae
    • C12N2795/14133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
CN201480030678.2A 2013-05-28 2014-05-28 包含具有减小的免疫原性的经修饰的噬菌体g3p氨基酸序列的多肽 Pending CN105473153A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361828004P 2013-05-28 2013-05-28
US61/828,004 2013-05-28
US201361828497P 2013-05-29 2013-05-29
US61/828,497 2013-05-29
PCT/US2014/039760 WO2014193935A1 (en) 2013-05-28 2014-05-28 Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity

Publications (1)

Publication Number Publication Date
CN105473153A true CN105473153A (zh) 2016-04-06

Family

ID=51168338

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480030678.2A Pending CN105473153A (zh) 2013-05-28 2014-05-28 包含具有减小的免疫原性的经修饰的噬菌体g3p氨基酸序列的多肽

Country Status (13)

Country Link
US (2) US9988444B2 (enExample)
EP (1) EP3003349B1 (enExample)
JP (1) JP2016526044A (enExample)
KR (1) KR20160010618A (enExample)
CN (1) CN105473153A (enExample)
AU (1) AU2014274253B2 (enExample)
CA (1) CA2913414A1 (enExample)
EA (1) EA030389B1 (enExample)
HK (1) HK1223285A1 (enExample)
MX (1) MX2015016263A (enExample)
PH (1) PH12015502585A1 (enExample)
SG (1) SG11201509647WA (enExample)
WO (1) WO2014193935A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107250154A (zh) * 2014-12-03 2017-10-13 普罗克拉拉生物科学股份有限公司 包含缺乏糖基化信号的经修饰的噬菌体g3p氨基酸序列的多肽
CN107384960A (zh) * 2017-07-25 2017-11-24 吉优诺（上海）基因科技有限公司 基于复制缺陷性重组腺病毒携带il‑17结合分子转基因载体及其构建方法和应用
CN114057858A (zh) * 2020-08-10 2022-02-18 北京太东生物科技有限公司 对引起神经变性和神经退行性疾病的蛋白聚集具有解聚作用的多肽

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013082114A1 (en) 2011-11-29 2013-06-06 Neurophage Pharmaceuticals, Inc. Use of p3 of bacteriophage as amyloid binding agents
NZ706838A (en) 2012-10-02 2017-06-30 Proclara Biosciences Inc Use of p3 of bacteriophage fusion proteins as amyloid binding agents
BR112020025111A2 (pt) 2018-06-15 2021-04-06 Proclara Biosciences, Inc. Motivo de interação amiloide geral (gaim)
US20240124889A1 (en) 2019-05-07 2024-04-18 Voyager Therapeutics, Inc. Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
BR112023001238A2 (pt) 2020-07-24 2023-04-04 Jawaharlal Nehru Centre For Advanced Scient Research Compostos de monoimida de naftaleno e métodos para os mesmos
EP4626416A1 (en) 2022-12-02 2025-10-08 Alzheon, Inc. Methods for treating neurodegenerative disorders with tramiprosate

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101166536A (zh) * 2005-02-01 2008-04-23 雷蒙特亚特特拉维夫大学有限公司 治疗与淀粉样蛋白沉积有关的炎症和涉及已活化小胶质细胞的脑部炎症的方法
WO2011084714A2 (en) * 2009-12-17 2011-07-14 Biogen Idec Ma Inc. STABILIZED ANTI-TNF-ALPHA scFv MOLECULES OR ANTI-TWEAK scFv MOLECULES AND USES THEREOF

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
US4215051A (en) 1979-08-29 1980-07-29 Standard Oil Company (Indiana) Formation, purification and recovery of phthalic anhydride
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
JP2989002B2 (ja) 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
DE10399023I2 (de) 1989-09-12 2006-11-23 Ahp Mfg B V TFN-bindende Proteine
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
ATE240740T1 (de) 1991-03-15 2003-06-15 Amgen Inc Pegylation von polypeptiden
JP3068301B2 (ja) * 1992-01-08 2000-07-24 三菱電機株式会社 Ｉｃカード内のコネクタ支持固定機構
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
DK0615451T3 (da) 1992-05-26 2006-04-24 Immunex Corp Hidtil ukendt cytokin der binder til CD30
ATE319745T1 (de) 1997-05-21 2006-03-15 Biovation Ltd Verfahren zur herstellung von nicht-immunogenen proteinen
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
US20020052311A1 (en) 1999-09-03 2002-05-02 Beka Solomon Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders
US8022270B2 (en) 2000-07-31 2011-09-20 Biolex Therapeutics, Inc. Expression of biologically active polypeptides in duckweed
BR0207267A (pt) 2001-02-19 2004-02-10 Merck Patent Gmbh Proteìnas artificiais com imunogenicidade reduzida
WO2002070548A2 (en) 2001-03-08 2002-09-12 Merck Patent Gmbh Modified human granulocyte macrophage colony stimulating factor (gm-csf) with reduced immunogenicity
DE10238846A1 (de) 2002-08-20 2004-03-04 Nemod Immuntherapie Ag Aktive Fusionsproteine und Verfahren zu ihrer Herstellung
US20090304726A1 (en) 2006-02-15 2009-12-10 Ramot At Tel Aviv University Ltd. Viral display vehicles for treating multiple sclerosis
AU2007214399A1 (en) 2006-02-15 2007-08-23 Ramot At Tel-Aviv University Filamentous bacteriophage displaying protein as a binder of antibodies and immunocomplexes for delivery to the brain
WO2007109733A2 (en) 2006-03-21 2007-09-27 The Johns Hopkins University Diagnostic and prognostic markers and treatment strategies for multiple sclerosis
EP2003200A4 (en) 2006-04-06 2009-09-02 Fumiaki Uchiyama PHAGIC EXPRESSION BY A NEW FILAMENTOUS BACTERIOPHAGE
EP2054515B1 (en) 2006-07-21 2012-01-11 Ramot at Tel-Aviv University Ltd. Use of a phage displaying a peptide from an adhesion protein for treating a disease associated with intracellular formation of protein fibrillar inclusions or aggregates
RU2009113455A (ru) 2006-10-11 2010-11-20 Антитоуп Лимитед (GB) Базы данных т-клеточных эпитопов
WO2009143465A1 (en) 2008-05-22 2009-11-26 Ramot At Tel Aviv University Ltd. Method of imaging abnormal deposits or plaques
BRPI0921557A2 (pt) 2008-11-24 2019-09-24 Univ Ramot bacteriófago filamentoso, primeiro e segundo bacteriófago filamentoso para o uso no tratamento do mal de parkinson, composição farmacêutica, e , método para tratar um paciente
CA2829223A1 (en) 2011-03-11 2012-09-20 Beka Solomon Method for treating neurodegenerative tauopathy
WO2013082114A1 (en) 2011-11-29 2013-06-06 Neurophage Pharmaceuticals, Inc. Use of p3 of bacteriophage as amyloid binding agents
NZ706838A (en) * 2012-10-02 2017-06-30 Proclara Biosciences Inc Use of p3 of bacteriophage fusion proteins as amyloid binding agents
BR112017011530A2 (pt) 2014-12-03 2018-03-13 Proclara Biosciences Inc polipeptídeos que compreendem uma sequência de aminoácidos g3p de bacteriófago modificada sem sinal de glicosilação

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101166536A (zh) * 2005-02-01 2008-04-23 雷蒙特亚特特拉维夫大学有限公司 治疗与淀粉样蛋白沉积有关的炎症和涉及已活化小胶质细胞的脑部炎症的方法
WO2011084714A2 (en) * 2009-12-17 2011-07-14 Biogen Idec Ma Inc. STABILIZED ANTI-TNF-ALPHA scFv MOLECULES OR ANTI-TWEAK scFv MOLECULES AND USES THEREOF

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107250154A (zh) * 2014-12-03 2017-10-13 普罗克拉拉生物科学股份有限公司 包含缺乏糖基化信号的经修饰的噬菌体g3p氨基酸序列的多肽
CN107384960A (zh) * 2017-07-25 2017-11-24 吉优诺（上海）基因科技有限公司 基于复制缺陷性重组腺病毒携带il‑17结合分子转基因载体及其构建方法和应用
CN107384960B (zh) * 2017-07-25 2020-06-12 吉优诺（上海）基因科技有限公司 基于复制缺陷性重组腺病毒携带il-17结合分子转基因载体及其构建方法和应用
CN114057858A (zh) * 2020-08-10 2022-02-18 北京太东生物科技有限公司 对引起神经变性和神经退行性疾病的蛋白聚集具有解聚作用的多肽
US11970517B2 (en) 2020-08-10 2024-04-30 Rejukon Biopharm Inc. Compositions and methods for dissolving protein aggregates

Also Published As

Publication number Publication date
US20160115223A1 (en) 2016-04-28
US20170129945A9 (en) 2017-05-11
AU2014274253A1 (en) 2016-01-21
EA030389B1 (ru) 2018-07-31
JP2016526044A (ja) 2016-09-01
US9988444B2 (en) 2018-06-05
EA201592272A1 (ru) 2016-04-29
SG11201509647WA (en) 2015-12-30
EP3003349A1 (en) 2016-04-13
MX2015016263A (es) 2016-04-18
PH12015502585A1 (en) 2016-02-29
EP3003349B1 (en) 2018-12-12
AU2014274253B2 (en) 2018-06-14
HK1223285A1 (zh) 2017-07-28
US20180251534A1 (en) 2018-09-06
WO2014193935A1 (en) 2014-12-04
KR20160010618A (ko) 2016-01-27
CA2913414A1 (en) 2014-12-04

Similar Documents

Publication Publication Date Title
US9988444B2 (en) Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity
US11723951B2 (en) Polypeptides comprising a modified bacteriophage G3P amino acid sequence lacking a glycosylation signal
JP6283366B2 (ja) アミロイド結合剤としてのバクテリオファージ融合タンパク質のｐ３の使用
CN100450551C (zh) 用于治疗和预防阿尔茨海默病的重组腺相关病毒基因疫苗及其用途
IL300346A (en) TAU vaccine for the treatment of Alzheimer's disease
JP7549536B2 (ja) 全般的アミロイド相互作用モチーフ（ｇａｉｍ）
HK1249520B (en) Polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a glycosylation signal
JP2023155237A (ja) サイクリン依存性キナーゼ５（ｃｄｋ５）阻害性ペプチド
CN117327168A (zh) B2M-GluN1封闭肽、其药物组合物及用途
JP2023547785A (ja) プリオン－Ｆｃ領域融合タンパク質及びそれらの使用
EP3675961A1 (en) Leptin peptides and their use for treating neurological disorders

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: Massachusetts, USA

Applicant after: Clara Biosciences Limited by Share Ltd

Address before: Massachusetts, USA

Applicant before: NEUROPHAGE PHARMACEUTICALS, INC.

CB02 Change of applicant information
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160406

WD01 Invention patent application deemed withdrawn after publication